Cancer Treatment Updates
February 12th, 2019
The 2019 Szent-Györgyi Prize for Progress in Cancer Research will be awarded to NCI’s Steven A. Rosenberg, M.D., Ph.D., for his pioneering role in the development of immunotherapy.
January 10th, 2019
A research team from NIH and Global Good has developed a computer algorithm that can analyze digital images of the cervix and identify precancerous changes that require medical attention. The AI approach could be valuable in low-resource settings.
January 9th, 2019
The BRCA Exchange, a global resource that includes data on thousands of inherited variants in the BRCA1/BRCA2 genes, is available to the public through a website and new smartphone app.
December 20th, 2018
In a new study, NIH investigators found that patients treated with chemotherapy for most solid tumors had an increased risk of tMDS/AML, a rare but often fatal blood cancer. The study, which used population-based data, was published in JAMA Oncology.
December 4th, 2018
A clinical trial showed that ibrutinib plus rituximab is superior to standard treatment for patients age 70 and younger with untreated chronic lymphocytic leukemia (CLL). Findings were announced at the American Society of Hematology annual meeting.
August 27th, 2018
Senator John McCain, a long-time supporter of cancer research, passed away on August 25.
August 20th, 2018
In a new study, NCI-led researchers developed a gene expression predictor that can indicate whether melanoma in a specific patient is likely to respond to treatment with immune checkpoint inhibitors, a type of immunotherapy.
August 15th, 2018
NCI’s Steven A. Rosenberg, M.D., Ph.D., and two NCI-supported researchers have been named recipients of the 2018 Albany Medical Center Prize in Medicine and Biomedical Research for their pioneering immunotherapy research.
Cetuximab with radiation found to be inferior to standard treatment in HPV-positive oropharyngeal cancer
August 14th, 2018
Results from a randomized clinical trial show patients with HPV-positive oropharyngeal cancer treated with radiation and cetuximab had inferior survival compared to the current standard treatment with radiation and cisplatin. The trial’s goal was to find a less toxic treatment approach without compromising survival.
NIH and Prostate Cancer Foundation launch large study on aggressive prostate cancer in African-American men
July 17th, 2018
RESPOND is the largest coordinated study on biological and non-biological factors associated with aggressive prostate cancer in African-American men. The study is an effort to learn why these men disproportionally experience aggressive disease.